• TickerNVCR
  • ISINJE00BYSS4X48
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryJersey

Analysts

ValuEngine Rating and Forecast Report for NVCR

ValuEngine Rating and Forecast Report for NVCR

2 directors sold

Two Directors at Novocure Ltd sold 61,213 shares at between 40.008USD and 40.026USD. The significance rating of the trade was 83/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. ...

ValuEngine Rating and Forecast Report for NVCR

ValuEngine Rating and Forecast Report for NVCR

ValuEngine Rating and Forecast Report for NVCR

ValuEngine Rating and Forecast Report for NVCR

ValuEngine Rating and Forecast Report for NVCR

ValuEngine Rating and Forecast Report for NVCR

ValuEngine Rating and Forecast Report for NVCR

ValuEngine Rating and Forecast Report for NVCR

Increased risk weighs on NOVOCURE, penalising its rating down to Slightly Negative

The independent financial analyst theScreener just lowered the general evaluation of NOVOCURE (US), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 2 out of 4 possible stars. Its market behaviour, however, has slightly deteriorated and will be qualified as risky moving forward. theScreener considers that these new qualifications justify an overall rating downgrade to Slightly Negative. As of the analysis date April 23, 2019, the closing price was USD 44.97 and its target price was estimated at USD 33.81.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch